Fraser Wright - Spark Therapeutics Insider

ONCE -- USA Stock  

USD 84.97  4.30  4.82%

Co-Founder and CTO
Dr. J. Fraser Wright Ph.D. is CoFounder and Chief Technology Officer of Spark Therapeutics Inc. From July 2013 until he joined Spark Dr. Wright served as our Chief Technology Advisor. Dr. Wright established and had been the director of the Clinical Vector Core Laboratory at CHOP from 2004 to January 2015. Dr. Wright also was a Professor at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wright previously served as Director of Development and Clinical Manufacturing at Avigen Inc. from 1999 to 2004 and as scientist with Sanofi Pasteur and as scholar investigator with the Canadian blood services
Age: 56  Founder Since 2015  Ph.D    
Wright received his B.S. and Ph.D. in biochemistry from the University of Toronto.

Management Efficiency

The company has return on total asset (ROA) of (28.14) % which means that it has lost $28.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.37) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 35.75 M in liabilities with Debt to Equity (D/E) ratio of 7.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has Current Ratio of 11.13 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 315 people.Spark Therapeutics (ONCE) is traded on BATS Exchange in USA. It is located in PENNSYLVANIA U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Spark Therapeutics Leadership Team

Romuald Corbau, Executive
Carol GrevePhilips, Executive
Robert Perez, Director
Lars Ekman, Director, Ph.D
Jennifer Wellman, Founder
Fraser Wright, Founder, Ph.D
Morgan Molloy, Executive
Lorris Betz, Director
Joseph Barge, Executive
Katherine High, President, Ph.D
Elliot Sigal, Director
John Furey, COO, MBA
Vincent Milano, Director
Lota Zoth, Director
Rogerio Coelho, Executive
Elliott Sigal, Director
Guang Qu, Executive
Daniel Takefman, Executive, Ph.D
Stephen Webster, CFO, MBA
Rogerio Vivaldi, Executive
Diane Blumenthal, Executive, MBA
Jeffrey Marrazzo, CEO, MBA
Daniel Faga, Executive, MBA
Anand Mehra, Director
Linda Hearne, Executive, MBA
Paul Gil, Executive, MBA
Charles Sigal, Director
Federico Mingozzi, Executive
Steven Altschuler, Chairman
Lisa Dalton, Executive, MBA

Stock Performance Indicators

Did you try this?

Run Pattern Recognition Now

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Pattern Recognition

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.